TY - JOUR
T1 - [18]F-fluoroethyl-L-tyrosine positron emission tomography for radiotherapy target delineation
T2 - Results from a Radiation Oncology credentialing program
AU - Barry, Nathaniel
AU - Koh, Eng Siew
AU - Ebert, Martin A.
AU - Moore, Alisha
AU - Francis, Roslyn J.
AU - Rowshanfarzad, Pejman
AU - Hassan, Ghulam Mubashar
AU - Ng, Sweet P.
AU - Back, Michael
AU - Chua, Benjamin
AU - Pinkham, Mark B.
AU - Pullar, Andrew
AU - Phillips, Claire
AU - Sia, Joseph
AU - Gorayski, Peter
AU - Le, Hien
AU - Gill, Suki
AU - Croker, Jeremy
AU - Bucknell, Nicholas
AU - Bettington, Catherine
AU - Syed, Farhan
AU - Jung, Kylie
AU - Chang, Joe
AU - Bece, Andrej
AU - Clark, Catherine
AU - Wada, Mori
AU - Cook, Olivia
AU - Whitehead, Angela
AU - Rossi, Alana
AU - Grose, Andrew
AU - Scott, Andrew M.
N1 - Publisher Copyright:
© 2024 The Author(s)
PY - 2024/4
Y1 - 2024/4
N2 - Background and purpose: The [18]F-fluoroethyl-L-tyrosine (FET) PET in Glioblastoma (FIG) study is an Australian prospective, multi-centre trial evaluating FET PET for newly diagnosed glioblastoma management. The Radiation Oncology credentialing program aimed to assess the feasibility in Radiation Oncologist (RO) derivation of standard-of-care target volumes (TVMR) and hybrid target volumes (TVMR+FET) incorporating pre-defined FET PET biological tumour volumes (BTVs). Materials and methods: Central review and analysis of TVMR and TVMR+FET was undertaken across three benchmarking cases. BTVs were pre-defined by a sole nuclear medicine expert. Intraclass correlation coefficient (ICC) confidence intervals (CIs) evaluated volume agreement. RO contour spatial and boundary agreement were evaluated (Dice similarity coefficient [DSC], Jaccard index [JAC], overlap volume [OV], Hausdorff distance [HD] and mean absolute surface distance [MASD]). Dose plan generation (one case per site) was assessed. Results: Data from 19 ROs across 10 trial sites (54 initial submissions, 8 resubmissions requested, 4 conditional passes) was assessed with an initial pass rate of 77.8 %; all resubmissions passed. TVMR+FET were significantly larger than TVMR (p < 0.001) for all cases. RO gross tumour volume (GTV) agreement was moderate-to-excellent for GTVMR (ICC = 0.910; 95 % CI, 0.708–0.997) and good-to-excellent for GTVMR+FET (ICC = 0.965; 95 % CI, 0.871–0.999). GTVMR+FET showed greater spatial overlap and boundary agreement compared to GTVMR. For the clinical target volume (CTV), CTVMR+FET showed lower average boundary agreement versus CTVMR (MASD: 1.73 mm vs. 1.61 mm, p = 0.042). All sites passed the planning exercise. Conclusions: The credentialing program demonstrated feasibility in successful credentialing of 19 ROs across 10 sites, increasing national expertise in TVMR+FET delineation.
AB - Background and purpose: The [18]F-fluoroethyl-L-tyrosine (FET) PET in Glioblastoma (FIG) study is an Australian prospective, multi-centre trial evaluating FET PET for newly diagnosed glioblastoma management. The Radiation Oncology credentialing program aimed to assess the feasibility in Radiation Oncologist (RO) derivation of standard-of-care target volumes (TVMR) and hybrid target volumes (TVMR+FET) incorporating pre-defined FET PET biological tumour volumes (BTVs). Materials and methods: Central review and analysis of TVMR and TVMR+FET was undertaken across three benchmarking cases. BTVs were pre-defined by a sole nuclear medicine expert. Intraclass correlation coefficient (ICC) confidence intervals (CIs) evaluated volume agreement. RO contour spatial and boundary agreement were evaluated (Dice similarity coefficient [DSC], Jaccard index [JAC], overlap volume [OV], Hausdorff distance [HD] and mean absolute surface distance [MASD]). Dose plan generation (one case per site) was assessed. Results: Data from 19 ROs across 10 trial sites (54 initial submissions, 8 resubmissions requested, 4 conditional passes) was assessed with an initial pass rate of 77.8 %; all resubmissions passed. TVMR+FET were significantly larger than TVMR (p < 0.001) for all cases. RO gross tumour volume (GTV) agreement was moderate-to-excellent for GTVMR (ICC = 0.910; 95 % CI, 0.708–0.997) and good-to-excellent for GTVMR+FET (ICC = 0.965; 95 % CI, 0.871–0.999). GTVMR+FET showed greater spatial overlap and boundary agreement compared to GTVMR. For the clinical target volume (CTV), CTVMR+FET showed lower average boundary agreement versus CTVMR (MASD: 1.73 mm vs. 1.61 mm, p = 0.042). All sites passed the planning exercise. Conclusions: The credentialing program demonstrated feasibility in successful credentialing of 19 ROs across 10 sites, increasing national expertise in TVMR+FET delineation.
KW - Clinical trials
KW - Credentialing
KW - FET PET
KW - Glioblastoma
KW - Treatment planning
UR - http://www.scopus.com/inward/record.url?scp=85189139186&partnerID=8YFLogxK
U2 - 10.1016/j.phro.2024.100568
DO - 10.1016/j.phro.2024.100568
M3 - Article
C2 - 38585372
AN - SCOPUS:85189139186
SN - 2405-6316
VL - 30
JO - Physics and Imaging in Radiation Oncology
JF - Physics and Imaging in Radiation Oncology
M1 - 100568
ER -